SCHEMBL30808243

SCHEMBL30808243

CNc1ncnc2c(OC)cccc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.59
ALDH1A1 P00352 5/20 0.52
HSD17B10 Q99714 5/20 0.52
CYP1A2 P05177 4/20 0.52
CYP3A4 P08684 4/20 0.52
TDP1 Q9NUW8 3/20 0.52
LMNA P02545 3/20 0.52
CYP2D6 P10635 3/20 0.52
CYP2C19 P33261 3/20 0.52
KDM4E B2RXH2 3/20 0.52
MAPK1 P28482 2/20 0.52
HPGD P15428 2/20 0.52
HTR1A P08908 2/20 0.50
ADRA1D P25100 2/20 0.50
ADRA1A P35348 2/20 0.50
ADRA1B P35368 2/20 0.50
PDE5A O76074 1/20 0.50
AURKA O14965 2/20 0.47
RPS6KB1 P23443 2/20 0.47
USP2 O75604 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16835554 0.80 PDE1B (0.66) ALDH1A1HSD17B10CYP1A2CYP3A4TDP1
SCHEMBL29853721 0.79 PDE5A (0.53) EGFRALDH1A1HSD17B10KDM4EMAPK1
SCHEMBL9206939 0.79 EGFR (0.66) EGFRALDH1A1HSD17B10CYP1A2CYP3A4
SCHEMBL9214074 0.77 EGFR (0.64) EGFRALDH1A1HSD17B10CYP1A2CYP3A4
SCHEMBL1039877 0.77 HTR1A (0.56) EGFRALDH1A1HSD17B10LMNAKDM4E
SCHEMBL31152241 0.77 PDE5A (0.43) ALDH1A1HSD17B10CYP1A2CYP3A4LMNA
SCHEMBL14843241 0.77 PDE5A (0.43) ALDH1A1HSD17B10CYP1A2CYP3A4LMNA
SCHEMBL3240985 0.77 HTR1A (0.50) EGFRALDH1A1CYP1A2CYP2C19HPGD
SCHEMBL11583026 0.77 HTR1A (0.50) EGFRALDH1A1HSD17B10KDM4EHPGD
SCHEMBL20813844 0.75 HTR1A (0.49) EGFRHPGDHTR1AADRA1DADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113039182-B Inhibitors of YAP/TAZ-TEAD interactions and their use in cancer treatment 伊文蒂瓦公司 2024-02-20 CN disclosed